Evidence map›Paper›PMID 40742091›Full record

ArticleCancer medicine2025

ASAP1 Promotes Epithelial to Mesenchymal Transition by Activating the TGFβ Pathway in Papillary Thyroid Cancer.

Shiji Song, Zixing Leng, Xinxin Zhao, Ziping Liu, Yongshuai Li, Wenjing Zhang, Junming Yue, Yuxia Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shiji SongDepartment of Thyroid Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Zixing LengDepartment of Thyroid Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Xinxin ZhaoDepartment of Gynecology and Obstetrics, The Third Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Ziping LiuDepartment of Gynecology and Obstetrics, The Third Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Yongshuai LiDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Wenjing ZhangDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Junming YueDepartment of Pathology and Laboratory Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Yuxia FanDepartment of Thyroid Surgery, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan, People's Republic of China.ORCID https://orcid.org/0000-0003-3045-5818

Funding

Young and middle-aged Health Science and Technology Innovation Talent of Henan Province YXKC2022010
6 · The paper itself

Abstract

backgroundPapillary thyroid cancer (PTC) is the most common type of thyroid malignancy. While the prognosis of PTC is generally favorable, some cases exhibit aggressive behavior, leading to metastasis and recurrence. ASAP1 (ArfGAP with SH3, ankyrin repeats, and PH domain 1), an ADP-ribosylation factor GTPase-activating protein, has been implicated in tumor metastasis. However, its role in PTC remains unclear.

methodsASAP1 expression in PTC was evaluated using TCGA and GEO databases. Studies in PTC cell lines (MDA-T32 and MDA-T85) included lentiviral-mediated knockdown and overexpression of ASAP1 to assess effects on epithelial-mesenchymal transition (EMT) marker expression, cell proliferation, and invasive capacity. TGFβ pathway activity was examined by p-SMAD2 Western blotting and luciferase reporter assays. ASAP1-SMAD2/3 interactions were analyzed using co-immunoprecipitation (CO-IP) and immunofluorescence.

resultsASAP1 was aberrantly upregulated in PTC. Lentiviral knockdown of ASAP1 in PTC cells suppressed the EMT process. Reduced ASAP1 expression also inhibited cell survival, proliferation, migration, invasion, and the expression of p-SMAD2 in the TGFβ pathway in PTC cells. Conversely, ASAP1 overexpression reversed these effects. Mechanistically, ASAP1 interacts with the SMAD2/3 complex, forming a positive feedback loop with TGFβ signaling that promotes EMT and cell invasiveness in PTC cells, which suggests its potential role in PTC metastasis.

conclusionsThese findings suggest that targeting ASAP1 may offer a novel therapeutic strategy to limit PTC metastasis by suppressing EMT and attenuating the TGFβ pathway.

Indexed as

Adaptor Proteins, Signal TransducingEpithelial-Mesenchymal TransitionThyroid Cancer, PapillaryThyroid NeoplasmsTransforming Growth Factor betaCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansSignal TransductionSmad2 ProteinSmad3 ProteinAdaptor Proteins, Signal TransducingASAP1 protein, humanSmad2 ProteinSMAD2 protein, humanSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor betaASAP1EMTinteractioninvasionPTCTGFβ

Identifiers

PMID40742091
PMCPMC12311982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.